Answers are grounded in this paper and cite their sources.
Bosentan, ambrisentan, and macitentan are endothelin receptor antagonists (ERAs), currently available in Australia for treatment of pulmonary arterial hypertension (PAH). This study assessed the comparative adherence of these ERAs for PAH in Australian patients.
No takes yet. Share an insight, caveat, or question.
Lau et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: